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Rates of aldosterone antagonist use after myocardial infarction remain poor over time among guideline eligible patients
background:  Aldosterone antagonists (AldA) improve survival after MI in patients with LV systolic dysfunction (LVEF<40%) and either clinical heart 
failure or diabetes. Use of AldA for this indication 3-14 days after MI, is class I by ACC/AHA and ESC guidelines. The US discharge prescription rate for 
AldA after MI among eligible patients is low (9.1%); however, how often these patients are started on AldA after discharge is not firmly established.
methods:  We retrospectively examined data for all Type I MI pts treated at a tertiary care center between Sep 2010 and Dec 2012; we identified 
those eligible for AldA without contraindications (serum Cr>2 mg/dl for women or >2.5 mg/dl for men, or serum K >5.0 mmol/l). AldA use was 
determined at discharge, at 14 days post MI, and again at a long term follow up (median 1.5 years, IQR 1.0-2.1).
results:  Among 372 MI patients, 48 were eligible for AldA at discharge, and 5/48 (11%) were prescribed AldA at discharge, and no additional 
patients were started on AldA within 14 days. At long term follow up, 8 (25%) were taking AldA (figure).
Conclusions:  At a large academic hospital, use of AldA post-MI among eligible patients was low, did not change in the post-discharge period, and 
remained low (25%) even after a median 1.5 years of follow up. Underuse of AldA, despite robust evidence of a mortality benefit, further elucidates a 
gap between guidelines and practice.
 
